Reference
Roman C, et al. Iatrogenesis in multiple sclerosis: What is the therapeutic risk of our disease modifying therapies? Multiple Sclerosis Journal 25 (Suppl. 2): 777-778 (plus poster) abstr. P1405, Sep 2019. Available from: URL: http://doi.org/10.1177/1352458519868081 [abstract]
Rights and permissions
About this article
Cite this article
Alemtuzumab/teriflunomide. Reactions Weekly 1802, 26 (2020). https://doi.org/10.1007/s40278-020-77944-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-77944-8